Risk Assessment of Drug-Drug Interactions

10
Nov, 2014

Risk Assessment of Drug-Drug Interactions

Drug-drug interactions (DDIs) cause unexpected adverse drug reactions and contribute to drug withdrawal from the market. Through inducing or inhibiting drug-processing proteins, a new drug could induce toxicity or diminish efficacy of other concomitant drugs, thus causing DDIs. The major drug-processing proteins involved in DDIs include phase I drug-metabolizing enzymes: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, […]